Match!
Yoshinobu Kondo
Yokohama City University
22Publications
6H-index
113Citations
Publications 23
Newest
Source
#1Takashi Miyazaki (YCU: Yokohama City University)H-Index: 4
#2Jun Shirakawa (YCU: Yokohama City University)H-Index: 16
Last.Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 13 authors...
Source
#1Sho Kinguchi (YCU: Yokohama City University)H-Index: 4
#2Hiromichi Wakui (YCU: Yokohama City University)H-Index: 17
Last.Kouichi Tamura (YCU: Yokohama City University)H-Index: 27
view all 29 authors...
The Y-AIDA study was designed to investigate the renal- and home blood pressure (BP)-modulating effects of add-on dapagliflozin treatment in Japanese individuals with type 2 diabetes mellitus (T2DM) and albuminuria. We conducted a prospective, multicenter, single-arm study. Eighty-six patients with T2DM, HbA1c 7.0–10.0%, estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m2, and urine albumin-to-creatinine ratio (UACR) ≥ 30 mg/g creatinine (gCr) were enrolled, and 85 of these patients ...
Source
#1Satsuki KawasakiH-Index: 6
#2Haruo MisawaH-Index: 14
Last.Yasuo TerauchiH-Index: 58
view all 5 authors...
Diabetics often have vascular diseases and other comorbidities. Sleep apnea syndrome (SAS) is a disorder characterized by repeated episodes of apnea and hypopnea during nocturnal sleep. Risk factors for SAS include obesity, male gender, and advanced age. It was reported that type 2 diabetes patients (T2DM) without obesity often have SAS. Among the 1,367 ambulant T2DM who were being treated at our institution, 245 (165 men, 80 women) with a BMI Disclosure S. Kawasaki: None. H. Misawa: None. T. Ko...
Source
#1Yoshinobu KondoH-Index: 6
#2Shinobu SatohH-Index: 20
Last.Yasuo TerauchiH-Index: 58
view all 3 authors...
Studies on glucagon-like peptide 1 receptor agonists (GLP-1-RA) and dipeptidyl peptidase-4 inhibitors (DPP-4-I) have suggested positive effects on beta-cells. However, direct comparison between weekly GLP-1-RA: dulaglutide (Dula) and weekly DPP-4-I: trelagliptin (Trela) effects on beta-cell function is not known. Thus, we compared the effects of Dula and Trela on beta-cell function in patients with type 2 diabetes (T2D) in an open-label, parallel-group, randomized controlled 24-week trial, with ...
Source
#2Yoshinobu KondoH-Index: 6
Last.Yasuo TerauchiH-Index: 58
view all 3 authors...
Liraglutide (Lira) and empagliflozin (Empa) have been reported to suppress cardiovascular events in large-scale clinical trials. However, reports of their long-term combined use with insulin therapy or direct comparisons of both drugs are limited. This open-label, parallel-group, randomized controlled trial aimed to compare the effects of Lira and Empa used in combination with insulin therapy in patients with type 2 diabetes (T2D). Adult outpatients with T2D undergoing stable insulin therapy wit...
Source
#2Yoshinobu KondoH-Index: 6
Last.Yasuo TerauchiH-Index: 58
view all 5 authors...
Reportedly, patients with type 2 diabetes at a high risk for cardiovascular events receiving empagliflozin, compared with placebo, have a lower rate of the primary composite cardiovascular outcome and death from any cause. This study compares the effect of empagliflozin and glimepiride on the endothelial function in patients with type 2 diabetes by flow-mediated dilation (FMD). This prospective, randomized, parallel-group comparison study enrolled 31 patients who were continuously treated with m...
Source
#1Yoshinobu KondoH-Index: 6
#2Shinobu SatohH-Index: 20
Last.Yasuo TerauchiH-Index: 58
view all 3 authors...
Some studies of glucagon-like peptide 1 receptor agonists (GLP-1-RA) and dipeptidyl peptidase-4 inhibitors (DPP-4-I) have shown positive effects on beta-cells. A direct comparison between weekly GLP-1-RA: dulaglutide (Dula) and weekly DPP-4-I: trelagliptin (Trela) effects on beta-cell function has not yet been performed. We compared the effects of Dula and Trela on beta-cell function in type 2 diabetes (T2D) patients in an open-label, parallel-group, randomized controlled trial. Patients receive...
Source
#1Kohei ItoH-Index: 1
#2Yoshinobu KondoH-Index: 6
Last.Yasuo TerauchiH-Index: 58
view all 4 authors...
Objective: In patients with diabetes, The use of GLP-1 receptor agonist expected to decreases the number of injections and improves blood glucose control. In this study, the effects were evaluated when changed from intensive insulin therapy to combination therapy of long-acting GLP-1 receptor agonist, duraglutide, and long-acting insulin. Methods: We examined patients with type 2 diabetes who were admitted to our department and started blood glucose management with intensive insulin therapy, fol...
1 CitationsSource
#1Satsuki KawasakiH-Index: 6
#2Haruo MisawaH-Index: 14
Last.Yasuo TerauchiH-Index: 58
view all 6 authors...
Diabetic patients often have various diseases such as vascular diseases and other comorbidities. Sleep apnea syndrome (SAS) in such patients may lead to acute deterioration due to nocturnal hypoxia. Among the 1,367 ambulant patients with type 2 diabetes (T2DM) who were being treated at our institution, 483 (313 men and 170 women) who agreed to undergo a portable sleep polygraph test were evaluated to identify risk factors for SAS, with a focus on microangiopathy and stable comorbidities. The rat...
Source
123